Company intelligence / Profile preview

Eman

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Eman Therapeutics is a pre-clinical stage biotechnology company focused on the development of next-generation RNA interference (RNAi) therapies. Founded by Dr. Muthiah (Mano) Manoharan, a pioneer in oligonucleotide chemistry and former senior executive at Alnylam Pharmaceuticals, the company aims to overcome current limitations in RNAi delivery and potency. Eman Therapeutics utilizes a proprietary platform to engineer small interfering RNAs (siRNAs) with enhanced chemical modifications and novel delivery ligands, targeting tissues beyond the liver. The company's mission is to create a new class of precision medicines for patients with genetic, metabolic, and other challenging diseases.

Therapeutic areas: Rare DiseasesMetabolic Disorders
Modalities: Small interfering RNARNA therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Eman.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eman.

Explore the full profile